![Michael Krebs](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Marcel Eggimann | M | - |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | 28 años |
Simon Wyss | M | - |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | 17 años |
Christoph Stuber | M | - |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | 16 años |
Oliver Szolar | M | - |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Pablo Hofbauer | M | - |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Sasha Mendjan | M | - |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Thomas Streimelweger | M | 65 |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Adrian C. Peter | M | - |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | 12 años |
Martin Würmli | M | 49 |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | 8 años |
Myriam Nepfer | F | - |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | 14 años |
Martin Parschalk | M | - |
Heartbeat.bio AG
![]() Heartbeat.bio AG Miscellaneous Commercial ServicesCommercial Services HeartBeat.bio AG is an Austrian company that specializes in developing a high-throughput human organoid screening platform for cardiac drug discovery. HeartBeat.bio is based in Vienna, AT, at the Biocenter. The company's technology platform is based on self-organizing, scalable cardiac organoids that replicate human heart physiology, allowing for modeling of various diseases such as drug-induced and genetic cardiomyopathies, myocardial infarction, heart remodeling, and regeneration. The company was founded in 2021 by a team with extensive experience in organoid research, drug discovery, and business development. Michael Krebs has been the CEO since incorporation. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Martin Boss | M | - |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | - |
Yves Lienhard | M | - |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | - |
Adriano Sbriglio | M | - |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | 3 años |
Yves Zumbrunnen | M | - |
Privatbank Von Graffenried AG
![]() Privatbank Von Graffenried AG Investment ManagersFinance Part of Von Graffenried Holding AG, Privatbank Von Graffenried AG is a Swiss company that provides investment advice. The company is based in Bern, Switzerland. The company was founded in 1979. Marcel Eggimann has been the CEO of the company since 1996. | 7 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Suiza | 10 | 66.67% |
Austria | 5 | 33.33% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Michael Krebs
- Red Personal